You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVeliparib
Accession NumberDB07232
TypeSmall Molecule
GroupsInvestigational
DescriptionNot Available
Structure
Thumb
Synonyms
(2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium
2-((2R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide
External Identifiers
  • ABT-888
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII01O4K0631N
CAS number912444-00-9
WeightAverage: 244.2923
Monoisotopic: 244.132411154
Chemical FormulaC13H16N4O
InChI KeyJNAHVYVRKWKWKQ-CYBMUJFWSA-N
InChI
InChI=1S/C13H16N4O/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17)/t13-/m1/s1
IUPAC Name
2-[(2R)-2-methylpyrrolidin-2-yl]-1H-1,3-benzodiazole-7-carboxamide
SMILES
C[C@@]1(CCCN1)C1=NC2=CC=CC(C(N)=O)=C2N1
Pharmacology
IndicationNot Available
Structured Indications Not Available
Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAccelerated Phase of Disease / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult T Acute Lymphoblastic Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Blastic Phase / Chronic Myelomonocytic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Disease / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentAdult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Essential Thrombocythemia (ET) / Hematopoietic and Lymphoid Cell Neoplasm / Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Disease / Secondary Myelodysplastic Syndromes1
1Active Not RecruitingTreatmentAdult Solid Neoplasm / BRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Estrogen Receptor Negative / HER2/Neu Negative / Hereditary Breast and Ovarian Cancer Syndrome / Male Breast Carcinoma / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Pancreatic Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Prostate Carcinoma / Triple-Negative Breast Carcinoma1
1Active Not RecruitingTreatmentAdult Solid Neoplasm / Peritoneal Carcinomatosis / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
1Active Not RecruitingTreatmentAdvanced Solid Tumors2
1Active Not RecruitingTreatmentBRCA Mutated / BRCA Mutated Breast Cancer / High Grade Serous Ovarian Cancer / Oncology1
1Active Not RecruitingTreatmentBRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Estrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Male Breast Carcinoma / Progesterone Receptor Negative / Progesterone Receptor Positive / Recurrent Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
1Active Not RecruitingTreatmentCancer, Breast1
1Active Not RecruitingTreatmentCancer, Breast / Cancer, Ovarian / Colon Cancer / Gastric Cancers / Lung Cancers / Tumors, Solid1
1Active Not RecruitingTreatmentCancer, Ovarian1
1Active Not RecruitingTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Hereditary Breast/Ovarian Cancer - BRCA1 / Hereditary Breast/Ovarian Cancer - BRCA2 / Male Breast Cancer / Progesterone Receptor-negative Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
1Active Not RecruitingTreatmentFallopian Tube Carcinosarcoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Neoplasm / Fallopian Tube Transitional Cell Carcinoma / Ovarian Brenner Tumor / Ovarian Carcinosarcoma / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Tumor / Ovarian Mucinous Adenocarcinoma / Ovarian Seromucinous Tumor / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
1Active Not RecruitingTreatmentLeukemias / Lymphoma NOS / Unspecified Adult Solid Tumor, Protocol Specific1
1Active Not RecruitingTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Cystadenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Ovarian Carcinoma1
1Active Not RecruitingTreatmentSolid Neoplasms1
1Active Not RecruitingTreatmentSolid Neoplasms / Stage III Non-Hodgkin Lymphoma / Stage IV Non-Hodgkin Lymphoma1
1CompletedNot AvailableCancer, Breast / Cancer, Ovarian / Colon Cancer / Gastric Cancers / Lung Cancers / Tumors, Solid1
1CompletedTreatmentAdult Solid Neoplasm / BRCA1 Mutation Carrier / BRCA2 Mutation Carrier1
1CompletedTreatmentAdult Solid Neoplasm / BRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Hereditary Breast and Ovarian Cancer Syndrome1
1CompletedTreatmentAdult Solid Neoplasm / Estrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Male Breast Carcinoma / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
1CompletedTreatmentAstrocytomas / Ependymomas / Medulloblastomas / PNET / Pontine Glioma1
1CompletedTreatmentBrain Diseases / Central Nervous System Diseases / Neoplasms Metastasis / Neoplasms, Brain / Nervous System Neoplasms1
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Fallopian Tube Cancer / Hepatocellular Carcinomas / Metastatic Melanoma / Non-hematologic Malignancies / Primary Peritoneal Cancer1
1CompletedTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood High-grade Cerebellar Astrocytoma / Childhood High-grade Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Childhood Low-grade Cerebellar Astrocytoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Brain Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Spinal Cord Neoplasm / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma1
1CompletedTreatmentGastric Cancers1
1CompletedTreatmentLeukemias / Lymphoma NOS / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentLocally Advanced Rectal Cancer1
1CompletedTreatmentLymphoma NOS / Neoplasms1
1CompletedTreatmentLymphoma NOS / Tumors, Solid1
1CompletedTreatmentProstate Cancers1
1CompletedTreatmentTumors, Solid2
1Not Yet RecruitingTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Neuroendocrine Neoplasms / Progesterone Receptor Negative / Stage IIB Cervical Cancer / Stage IIIA Cervical Cancer / Stage IIIB Cervical Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Cervical Cancer / Stage IV Gastric Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Cancer / Stage IV Small Cell Lung Carcinoma / Triple-Negative Breast Carcinoma1
1RecruitingTreatmentAdult Hodgkin Lymphoma / Adult Non-Hodgkin's Lymphoma / Carcinoma, Breast / Carcinoma, Pancreatic / Colon Carcinoma / Estrogen Receptor Negative / HER2/Neu Negative / Lung Carcinoma / Metastatic Malignant Neoplasm / Ovarian Carcinoma / Progesterone Receptor Negative / Solid Neoplasms / Stage III Lung Cancer / Stage III Pancreatic Cancer / Stage IIIA Breast Cancer / Stage IIIA Colon Cancer / Stage IIIA Ovarian Cancer / Stage IIIB Breast Cancer / Stage IIIB Colon Cancer / Stage IIIB Ovarian Cancer / Stage IIIC Breast Cancer / Stage IIIC Colon Cancer / Stage IIIC Ovarian Cancer / Stage IV Breast Cancer / Stage IV Lung Cancer / Stage IV Ovarian Cancer / Stage IVA Colon Cancer / Stage IVA Pancreatic Cancer / Stage IVB Colon Cancer / Stage IVB Pancreatic Cancer / Triple-Negative Breast Carcinoma / Unresectable Malignant Neoplasm1
1RecruitingTreatmentAdvanced Malignant Neoplasm / BRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Solid Neoplasms1
1RecruitingTreatmentBladder Carcinoma / Carcinoma of Unknown Primary Origin / Carcinoma, Breast / Endometrial Carcinoma / Esophageal Carcinoma / Lung Carcinoma / Malignant Head and Neck Neoplasm / Melanoma / Neoplasms, Ovarian / Renal Pelvis and Ureter Urothelial Carcinoma / Testicular Lymphoma / Urethral Carcinoma1
1RecruitingTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Male Breast Carcinoma / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
1RecruitingTreatmentHER2/Neu Negative / Recurrent Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1RecruitingTreatmentPancreatic Cancers1
1RecruitingTreatmentSmall Cell Lung Cancer (SCLC)1
1RecruitingTreatmentStage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer1
1TerminatedTreatmentAdenocarcinoma of the Pancreas / Adenocarcinoma of the Stomach / BRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Ovarian Mucinous Cystadenocarcinoma / Recurrent Breast Cancer / Recurrent Colon Cancer / Recurrent Gastric Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Pancreatic Cancer / Recurrent Rectal Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Colon Cancer / Stage IV Gastric Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Stage IV Pancreatic Cancer / Stage IV Rectal Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentAdvanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Stage III Pancreatic Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Bladder Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Transitional Cell Carcinoma of the Bladder / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer1
1WithdrawnTreatmentNeoplasms1
1, 2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
1, 2Active Not RecruitingTreatmentCarcinoma of Unknown Primary Origin / Carcinoma, Small Cell / Extensive Stage Small Cell Lung Carcinoma / Large Cell Lung Carcinoma / Neuroendocrine Carcinomas / Newly Diagnosed Carcinoma of Unknown Primary Origin / Stage IV Non-Small Cell Lung Cancer1
1, 2Active Not RecruitingTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma / Stage IVB Cervical Cancer1
1, 2Active Not RecruitingTreatmentChildhood Mixed Glioma / Untreated Childhood Anaplastic Astrocytoma / Untreated Childhood Brain Stem Glioma / Untreated Childhood Fibrillary Astrocytoma / Untreated Childhood Giant Cell Glioblastoma / Untreated Childhood Glioblastoma / Untreated Childhood Gliosarcoma1
1, 2CompletedTreatmentAdult B Acute Lymphoblastic Leukemia / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Solid Neoplasm / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Lymphomatous Involvement of Non-Cutaneous Extranodal Site / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Nodal Marginal Zone Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides and Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Plasma Cell Myeloma / Small Intestinal Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors1
1, 2CompletedTreatmentCancer, Ovarian1
1, 2CompletedTreatmentRecurrent, Epithelial Ovarian Cancer1
1, 2RecruitingTreatmentBronchioloalveolar Carcinoma / Large Cell Lung Carcinoma / Lung Adenocarcinoma / Lung Adenocarcinoma, Mixed Subtype / Squamous Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
1, 2RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Human Papillomavirus Infections / Salivary Gland Squamous Cell Carcinoma / Stage IVA Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Oropharyngeal Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Hypopharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Oropharyngeal Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma1
1, 2RecruitingTreatmentPancreatic Cancer Metastatic1
1, 2SuspendedTreatmentAdult Solid Neoplasm / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2Active Not RecruitingTreatmentBRCA1 Gene Mutation / Brca2 Gene Mutation / Cancer, Breast / Metastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentBRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Ovarian Epithelial Tumor / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2Active Not RecruitingTreatmentBRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Recurrent Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2Active Not RecruitingTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Cervical Small Cell Carcinoma / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma / Stage III Cervical Cancer / Stage IVA Cervical Cancer / Stage IVB Cervical Cancer1
2Active Not RecruitingTreatmentHepatocellular Carcinomas1
2Active Not RecruitingTreatmentHormone-Resistant Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentRecurrent Small Cell Lung Carcinoma1
2Active Not RecruitingTreatmentUntreated Metastatic Colorectal Cancer1
2CompletedTreatmentBrain Metastases From Non-small Cell Lung Cancer1
2CompletedTreatmentCancer, Ovarian1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentMelanoma / Metastatic Melanoma / Skin Cancers1
2CompletedTreatmentNon-Small -Cell Lung Cancer1
2CompletedTreatmentSolid Tumor Cancers1
2RecruitingTreatmentBRCA1 Gene Mutation / Brca2 Gene Mutation / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentBRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentBRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Metastatic Pancreatic Adenocarcinoma / PALB2 Gene Mutation / Pancreatic Adenocarcinoma / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2RecruitingTreatmentCancer, Breast / Neoplasms, Breast / Tumors, Breast1
2RecruitingTreatmentLocally Advanced Non-Small Cell Lung Cancer1
2RecruitingTreatmentMetastatic Pancreatic Adenocarcinoma / Recurrent Pancreatic Carcinoma / Stage IV Pancreatic Cancer1
2RecruitingTreatmentMetastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)1
2RecruitingTreatmentRectal Adenocarcinoma / Stage II Rectal Cancer / Stage III Rectal Cancer1
2SuspendedTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-negative Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
2, 3SuspendedTreatmentGlioblastomas / Gliosarcoma1
3RecruitingTreatmentCancer, Ovarian / Neoplasms, Ovarian1
3RecruitingTreatmentMetastatic Breast Cancer (MBC)1
3RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer1
3RecruitingTreatmentSquamous Non-Small Cell Lung Cancer1
3RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
Not AvailableAvailableNot AvailableMetastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation / Triple-Negative Breast Cancer (TNBC)1
Not AvailableRecruitingTreatmentMetastatic Triple Negative Breast Cancer1
Not AvailableRecruitingTreatmentNeoplasms / Neoplasms, Advanced Solid / Recurrent Solid Neoplasm1
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Poly [ADP-ribose] polymerase 1ProteinunknownNot AvailableHumanP09874 details
Poly [ADP-ribose] polymerase 2ProteinunknownNot AvailableHumanQ9UGN5 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Veliparib.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Veliparib.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Veliparib.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Veliparib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Veliparib.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Veliparib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Veliparib.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Veliparib.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Veliparib.Approved, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Veliparib.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Veliparib.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Veliparib.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9597
Caco-2 permeable-0.6466
P-glycoprotein substrateSubstrate0.7841
P-glycoprotein inhibitor INon-inhibitor0.9381
P-glycoprotein inhibitor IINon-inhibitor0.8982
Renal organic cation transporterNon-inhibitor0.7994
CYP450 2C9 substrateNon-substrate0.8283
CYP450 2D6 substrateNon-substrate0.7684
CYP450 3A4 substrateNon-substrate0.5438
CYP450 1A2 substrateInhibitor0.5173
CYP450 2C9 inhibitorNon-inhibitor0.7135
CYP450 2D6 inhibitorNon-inhibitor0.8155
CYP450 2C19 inhibitorNon-inhibitor0.652
CYP450 3A4 inhibitorNon-inhibitor0.8474
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8153
Ames testNon AMES toxic0.7068
CarcinogenicityNon-carcinogens0.9098
BiodegradationNot ready biodegradable0.9874
Rat acute toxicity2.4847 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9961
hERG inhibition (predictor II)Non-inhibitor0.5162
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.275 mg/mLALOGPS
logP1.1ALOGPS
logP0.18ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)9.21ChemAxon
pKa (Strongest Basic)8.97ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area83.8 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity68.62 m3·mol-1ChemAxon
Polarizability26.31 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassNot Available
Direct ParentBenzimidazoles
Alternative Parents
Substituents
  • Benzimidazole
  • Aralkylamine
  • Benzenoid
  • Azole
  • Imidazole
  • Pyrrolidine
  • Heteroaromatic compound
  • Amino acid or derivatives
  • Carboxamide group
  • Primary carboxylic acid amide
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Secondary amine
  • Azacycle
  • Organic oxide
  • Organooxygen compound
  • Organonitrogen compound
  • Organopnictogen compound
  • Amine
  • Organic oxygen compound
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. Mediates the poly(ADP-ribosyl)ation of APLF and CHFR...
Gene Name:
PARP1
Uniprot ID:
P09874
Molecular Weight:
113082.945 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Nad+ adp-ribosyltransferase activity
Specific Function:
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks.
Gene Name:
PARP2
Uniprot ID:
Q9UGN5
Molecular Weight:
66205.31 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on September 15, 2010 15:19 / Updated on August 17, 2016 12:24